MATINAS BIOPHARMA
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal... infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
MATINAS BIOPHARMA
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2011-01-01
Address:
Tarpon Springs, Florida, United States
Country:
United States
Website Url:
http://www.matinasbiopharma.com
Total Employee:
11+
Status:
Active
Contact:
1(908) 443-1860
Email Addresses:
[email protected]
Total Funding:
58.74 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network
Similar Organizations
Chiasma
Chiasma is a biopharmaceutical company developing oral drugs for the treatment of orphan diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2015-01-30 | Aquarius Biotechnologies | Aquarius Biotechnologies acquired by MATINAS BIOPHARMA | N/A |
Investors List
SternAegis
SternAegis investment in Venture Round - MATINAS BIOPHARMA
Key Employee Changes
Official Site Inspections
http://www.matinasbiopharma.com
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149